Companies › Aegle Therapeutics
1 active drug program in 1 registered trial: 1 Phase 1; Other.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| AGLE-102 Extracellular vesicles derived from bone marrow-derived mesenchymal stem cells | – | Phase 1 | Dystrophic Epidermolysis Bullosa | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04173650 | AGLE-102 | Phase 1 | Dystrophic Epidermolysis Bullosa | Other | Sep 2025 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.